CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.
The discovery of JAK2 mutations in Philadelphia-negative myeloproliferative neoplasms has prompted investigators to evaluate mutation-targeted treatments to restore hematopoietic cell functions in these diseases. However, the results of the first clinical trials with JAK2 inhibitors are not as promising as expected, prompting a search for additional drugable targets to treat these disorders. In this paper, we used the hypomorphic Gata1(low) mouse model of primary myelofibrosis (PMF), the most severe of these neoplasms, to test the hypothesis that defective marrow hemopoiesis and development of extramedullary hematopoiesis in myelofibrosis is due to insufficient p27(Kip1) activity and is treatable by Aplidin, a cyclic depsipeptide that activates p27(Kip1) in several cancer cells. Aplidin restored expression of Gata1 and p27(Kip1) in Gata1(low) hematopoietic cells, proliferation of marrow progenitor cells in vitro and maturation of megakaryocytes in vivo (reducing TGF-beta/VEGF levels released in the microenvironment by immature Gata1(low) megakaryocytes). Microvessel density, fibrosis, bone growth, and marrow cellularity were normal in Aplidin-treated mice and extramedullary hematopoiesis did not develop in liver although CXCR4 expression in Gata1(low) progenitor cells remained low. These results indicate that Aplidin effectively alters the natural history of myelofibrosis in Gata1(low) mice and suggest this drug as candidate for clinical evaluation in PMF.
Verrucci
Maria
M
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Pancrazzi
Alessandro
A
Aracil
Miguel
M
Martelli
Fabrizio
F
Guglielmelli
Paola
P
Zingariello
Maria
M
Ghinassi
Barbara
B
D'Amore
Emanuela
E
Jimeno
José
J
Vannucchi
Alessandro M
AM
Migliaccio
Anna Rita
AR
D017677:Age Distribution; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001854:Bone Marrow Cells; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000378:metabolism; D047630:Depsipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D050982:GATA1 Transcription Factor / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects; D008297:Male; D051379:Mice; D009154:Mutation; D010456:Peptides, Cyclic; D055728:Primary Myelofibrosis / Q000235:genetics* / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000378:metabolism*; D013234:Stem Cells / Q000378:metabolism; D015431:Weight Loss / Q000187:drug effects
D000970:Antineoplastic Agents; C514936:CXCR4 protein, mouse; C493961:Cdkn1b protein, mouse; D047630:Depsipeptides; D050982:GATA1 Transcription Factor; C494689:Gata1 protein, mouse; D010456:Peptides, Cyclic; D019718:Receptors, CXCR4; D050760:Cyclin-Dependent Kinase Inhibitor p27; C098980:plitidepsin
J Histochem Cytochem. 2007 Jul;55(7):745-52
17371937
Cell Death Differ. 2006 Nov;13(11):1968-81
16543941
Blood. 2007 Aug 15;110(4):1092-7
17488875
Ann Oncol. 2005 Oct;16(10):1667-74
16014640
Science. 2003 Oct 17;302(5644):459-62
14564011
Cancer Res. 2007 Jul 1;67(13):6417-24
17616702
Stem Cells. 2008 Aug;26(8):1920-30
18511598
Nat Med. 2000 Nov;6(11):1235-40
11062534
Leukemia. 2008 Jan;22(1):23-30
17882282
Br J Cancer. 2008 Jun 17;98(12):1966-74
18521088
Oncol Rep. 2006 Nov;16(5):1099-103
17016599
Leukemia. 2003 Jan;17(1):52-9
12529660
Cancer Chemother Pharmacol. 2006 Jan;57(1):7-14
16001179
Clin Cancer Res. 2005 Nov 1;11(21):7664-73
16278386
Cancer Cell. 2005 Jan;7(1):51-63
15652749
Mol Biol Cell. 2005 Mar;16(3):1469-80
15647380
Science. 2003 Oct 17;302(5644):445-9
14564009
Cell. 2008 Apr 18;133(2):340-53
18423204
Nat Med. 2005 Aug;11(8):886-91
16025125
Exp Hematol. 2008 Feb;36(2):158-71
18206727
Expert Rev Hematol. 2009 Jun 1;2(3):315-334
20352017
Am J Pathol. 2005 Sep;167(3):849-58
16127162
Cancer J. 2007 Nov-Dec;13(6):377-83
18032975
J Bone Miner Res. 2004 Apr;19(4):652-60
15005853
Cell. 2008 Feb 22;132(4):631-44
18295580
Br J Cancer. 2004 Jun 14;90(12):2418-24
15173857
Blood. 2005 May 1;105(9):3493-501
15665119
Mol Cancer Ther. 2007 Apr;6(4):1310-6
17431109
Mol Cell Biol. 2009 Feb;29(4):986-99
19075005
Blood. 2007 Feb 15;109(4):1460-71
17038527
N Engl J Med. 2000 Apr 27;342(17):1255-65
10781623
Proc Natl Acad Sci U S A. 1990 Jan;87(2):668-72
2300555
Exp Hematol. 2003 Nov;31(11):1104-11
14585376
J Pharmacol Exp Ther. 2008 Mar;324(3):1093-101
18089842
Blood. 2005 Dec 15;106(13):4102-13
16109774
Blood. 2009 Aug 6;114(6):1150-7
19401558
Eur J Cancer. 2002 Jul;38(10):1395-404
12091072
Cancer Res. 2008 Jul 1;68(13):5216-25
18593922
J Cell Physiol. 2010 May;223(2):460-70
20112287
Curr Opin Investig Drugs. 2009 Jun;10(6):536-42
19513942
Blood. 2009 Sep 3;114(10):2107-20
19571316
Clin Adv Hematol Oncol. 2009 May;7(5):334-42
19521323
Curr Opin Hematol. 2008 Jan;15(1):49-58
18043246
Blood. 2008 Oct 15;112(8):3026-35
18669872
Br J Cancer. 1998 Sep;78(6):739-44
9743292
Mol Cell Biol. 2009 Sep;29(18):5168-80
19620289